大塚ホールディングス competitors & alternatives

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.600196 · PharmaceuticalsShanghai, China

64% matchPublic

Similar pharmaceuticals company

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, cardiovascular system, and APIs and intermediates. It also offers mRNA vaccines; medical aesthetic devices, such as medical aesthetic capital equipment, aesthetic dentistry, injectables, and personal care business units; mechanical ventilation devices under the Breas brand; and mobile pre-hospital care; professional in-hospital surgery and covers medical devices; and high-end surgical robots and medical consumables. In addition, the company provides diagnostics solutions comprising biochemical diagnostics, immune diagnostics, molecular diagnostics, microbiological diagnostics, pathological diagnostics, and chronic care management; and healthcare services, specialized medical treatment, online and offline medical services, and insurance services. Further, it engages in the operation of hospitals; and distribution and retail of healthcare products. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.

Similar pharmaceuticals company

Established in 1913 and headquartered in Tokyo, Japan, Mochida Pharmaceutical Co., Ltd. specializes in the development, manufacturing, and distribution of a wide array of medical and personal care products. Its primary offerings encompass pharmaceuticals, diagnostic solutions, and skincare lines. The company's extensive pharmaceutical portfolio includes treatments for a variety of conditions, such as cardiovascular issues, pain (analgesics), gastrointestinal ailments, neurological disorders, infections (anti-infectives), diabetes (antidiabetics), and cancer (oncological agents). Additionally, it provides hormone and biological preparations, alongside biosimilars, catering to therapeutic areas like dermatology, psychiatry, obstetrics, and gynecology. In diagnostics, Mochida produces various reagents, particularly those utilized for fertility and infertility assessments. Its skincare division features products designed for facial, body, and hair care. Beyond its existing product range, Mochida Pharmaceutical actively invests in research and development, with a specific focus on creating therapies for intractable diseases. The company has also forged strategic collaborations, including a partnership with Amarin Corporation plc for the advancement and market introduction of ethyl icosapentate products. Furthermore, it collaborates with Gene Techno Science Co., Ltd. to innovate regenerative medicine targeting rare and challenging digestive disorders, such as congenital isolated hypoganglionosis.

Similar pharmaceuticals company

Morishita Jintan Co., Ltd. is a Japanese enterprise that manufactures and distributes a diverse array of products, encompassing pharmaceuticals, quasi-pharmaceuticals, medical devices, and food items. The company's operations are divided into two main segments: Healthcare Business and Capsule Business. The Healthcare Business division is responsible for the production and sale of its proprietary Jintan branded goods, and also provides original equipment manufacturing (OEM) services for dietary supplements, cosmetic products, and various food items. Concurrently, the Capsule Business division handles both original equipment and design manufacturing (OEM/ODM) for pharmaceutical and food sectors, in addition to innovating and developing capsules for industrial applications. Established in 1893, the company's headquarters are located in Osaka, Japan.

Similar pharmaceuticals company

Fuso Pharmaceutical Industries, Ltd. is a Japanese firm primarily involved in the development and commercialization of pharmaceutical goods. Their product range encompasses prescription medications, particularly injectables and solutions for artificial kidney dialysis, as well as various medical instruments and apparatus. Additionally, the company participates in real estate leasing. Established in 1937, Fuso Pharmaceutical's corporate headquarters are situated in Osaka, Japan.

Similar pharmaceuticals company

Shionogi & Co., Ltd. is a Japanese enterprise focused on the entire lifecycle of pharmaceutical products, diagnostic tools, and medical equipment, encompassing their investigation, creation, production, and supply within Japan. The company's marketed portfolio includes Fetroja, a therapy for multidrug-resistant gram-negative bacterial infections; Xofluza, an antiviral medication targeting influenza; and Tivicay, which is used in HIV management. Shionogi actively pursues the development of numerous compounds addressing a wide array of medical conditions. Its investigational pipeline features treatments for opioid-induced constipation (Symproic); inflammatory pain (S-120083); neuropathic pain (S-010887, sivopixant, and S-637880 for low back pain); insomnia (S-117957); and central nervous system disorders such as sleep apnea syndrome, refractory/unexplained chronic cough (both sivopixant), depression (Zuranolone), and attention-deficit/hyperactivity disorder (SDT-001). The company also has candidates for Fragile X syndrome and Alzheimer's disease (BPN14770), as well as obesity (S-237648, S-309309). Its robust research pipeline further extends to treatments for conditions including decompensated liver cirrhosis (ADR-001) and NASH (S-723595). In oncology, Shionogi is advancing S-588410 for esophageal and bladder cancers, S-488210 for head and neck squamous cell carcinoma, and S-588210, S-222611, and S-531011 for various solid tumors and malignancies. Other investigational therapies include S-770108 for idiopathic pulmonary fibrosis, SR-0379 for cutaneous ulcers, S-005151 for stroke and epidermolysis bullosa, and S-0373 for spinocerebellar ataxia. The company is also heavily invested in COVID-19 therapeutics, with S-600918, S-217622, and S-555739 aimed at treating the virus and managing its worsening effects. Additionally, Shionogi provides diagnostic antibody test kits specifically for COVID-19. Shionogi & Co., Ltd. collaborates with academic and research institutions like Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University on joint initiatives, particularly in the development of antimalarial medications. Founded in Osaka, Japan, in 1878, the organization initially operated under the name Shionogi Shoten Co., Ltd. before adopting its current corporate identity, Shionogi & Co., Ltd., in 1943.

Similar pharmaceuticals company

Santen Pharmaceutical Co., Ltd. is headquartered in Osaka, Japan, and is a global leader in ophthalmological research, development, production, and marketing of related pharmaceuticals and medical devices.

Similar pharmaceuticals company

Kubota Pharmaceutical Holdings Co., Ltd., an international entity established in Tokyo, Japan, in 2002, focuses on the creation and advancement of a diverse range of pharmaceutical treatments and medical devices. A primary asset in their development pipeline is emixustat hydrochloride, a drug currently undergoing Phase III clinical trials for Stargardt disease and Phase II trials for proliferative diabetic retinopathy. Beyond its pharmaceutical endeavors, the company is also innovating in medical technology, specifically with a patient-centric ophthalmology suite designed for remote retinal monitoring. This advanced suite features both miniature, home-use optical coherence tomography (OCT) devices and high-resolution OCT technology adapted from NASA. Furthermore, Kubota Pharmaceutical Holdings is developing a wearable device aimed at controlling myopia.

Similar pharmaceuticals company

Nippon Chemiphar Co., Ltd., alongside its subsidiaries, is a global pharmaceutical entity engaged in the research, production, marketing, and sale of ethical drugs and diagnostic agents. Its diagnostic product lineup features the IgE NC kit, which measures overall IgE levels and identifies 57 specific allergens, as well as the DP3000 device for accurate allergen-specific IgE testing. The company's development pipeline includes NC-2400, a PPAR-delta agonist; NC-2500, a novel xanthine oxidoreductase inhibitor targeting hyperuricemia and gout; and NC-2600, a P2X4 receptor antagonist for neuropathic pain. Additionally, it is advancing NC-2700, a new urate transporter 1 inhibitor designed to enhance urinary urate excretion, and NC-2800, a delta opioid receptor agonist for treating depression and anxiety. Its commercialized pharmaceuticals comprise Uralyt-U (an alkalization therapeutic), Soleton (an analgesic and anti-inflammatory medication), and Calvan (a drug for hypertension). Beyond pharmaceuticals, Nippon Chemiphar offers a variety of quasi-drugs, nutritional supplements, health foods, cosmetics, and different types of creams. Its generic medications reach hospitals and pharmacies via wholesale distributors. Founded in Tokyo, Japan, in 1950, the company was initially known as Hitachi Chemical Co., Ltd., changing its name to Nippon Chemiphar Co., Ltd. in 1970.

Similar pharmaceuticals company

Sanwa Kagaku Kenkyusho Co., Ltd. is a Japanese pharmaceutical company that develops and manufactures prescription medicines, diagnostic reagents, and related medical products. It primarily serves healthcare professionals, hospitals, laboratories, and patients in Japan, with a notable focus on diabetes and other chronic diseases.

ＰＨＣホールディングス6523 · HealthtechTokyo, Japan

65% matchPublic

Healthtech

PHC Holdings Corporation, through its network of subsidiaries, specializes in the innovation, production, and sale of medical instruments, advanced healthcare technology solutions, and life science merchandise. The company's product line includes blood glucose monitoring systems and a variety of other diagnostic and analytical tools, alongside sophisticated data integration platforms. It also delivers end-to-end anatomical pathology solutions, featuring specialized equipment, microscope slides, and diverse staining reagents. In the life sciences sector, PHC provides essential equipment and support services for sample preservation and cell culture. Furthermore, the company develops and deploys healthcare IT products, focusing on medical information systems designed for clinics and pharmacies dealing with health insurance. Its operations also extend to clinical testing, the manufacturing of diagnostic reagents, and providing support for pharmaceutical development. Established in 2014 and based in Tokyo, Japan, the company was formerly recognized as Panasonic Healthcare Holdings Co., Ltd. before officially changing its name to PHC Holdings Corporation in April 2018.

Biotech

Takara Bio Inc., together with its subsidiaries, engages in the businesses of reagents, equipment, contract services, and genetic medicine in Japan, China, the rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including reagents needed for genetic and cellular research, PCR instruments, cellular analysis devices, and in vitro diagnostics for COVID-19 testing. It also provides contract services related to regenerative medicine products and contract services related to gene analysis and testing. In addition, the company is involved in commercialization of its proprietary platform technology for biologics development; development, manufacture, and sale of manufacture ancillary materials, such as RetroNectin that is used in the manufacture of gene therapy product; application for marketing authorization of NY-ESO-1 siTCR gene therapy product; and development of JAK/STAT technology suitable for CAR gene therapy and applied development of CereAAV, a brain-tropic adeno-associated virus vector. It provides its products and services through sales agents or directly to its customers. The company was incorporated in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.

Biotech

Operating from Tokyo, Japan since its establishment in 2012, Tsubota Laboratory Incorporated is dedicated to the research and development of pharmaceutical products and medical devices, specifically targeting the treatment of myopia, dry eyes, and presbyopia.